Literature DB >> 19301062

A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.

Paola Caramaschi1, Nicola Martinelli, Alessandro Volpe, Sara Pieropan, Ilaria Tinazzi, Giuseppe Patuzzo, Helal Mahamid, Lisa Maria Bambara, Domenico Biasi.   

Abstract

A single series of patients affected by systemic sclerosis (SSc) and cyclically treated with iloprost was reviewed in order to evaluate the incidence of digital ulcers (DUs) and to compare the characteristics between the patients with and without this painful and disabling vascular complication. The record charts of 85 SSc patients were revised. Ischemic DUs and scleroderma contracture ulcers were separately considered. Twenty-nine subjects developed ischemic DUs during the course of the disease; whereas, scleroderma contracture ulcers occurred in six subjects. Ischemic DUs were associated with younger age at scleroderma onset, a longer disease duration, a longer time delay from scleroderma diagnosis to iloprost therapy, a bigger skin involvement, the presence of joint contractures, a videocapillaroscopic late pattern, a history of smoking, and of corticosteroids therapy. After the exclusion of four subjects with concomitant peripheral arterial disease, a forward-stepwise logistic regression analysis showed that only four variables, i.e., age at scleroderma onset, delay in beginning iloprost therapy, history of smoking, and presence of joint contractures remained significantly associated with ischemic DUs. In a score reflecting the sum of these four risk factors, the prevalence of ischemic DUs increased progressively from the lowest to the highest value of the score. The predictivity of this model was evaluated by the receiver-operating characteristics curve, with an estimated area under the curve of 0.836 with 95% confidence interval from 0.736 to 0.937. All the patients with scleroderma contracture ulcers were characterized by both diffuse pattern of disease and positivity for anti-Scl70 antibody. In this retrospective study, scleroderma patients with ischemic DUs are characterized by early disease onset, delay in beginning iloprost therapy, smoking habit, and presence of joint contraction. A score reflecting the sum of these factors may be useful to predict the risk of developing ischemic DUs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19301062     DOI: 10.1007/s10067-009-1155-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  29 in total

Review 1.  Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients.

Authors:  Clodoveo Ferri; Gabriele Valentini; Franco Cozzi; Marco Sebastiani; Claudio Michelassi; Giovanni La Montagna; Arianna Bullo; Massimiliano Cazzato; Enrico Tirri; Franca Storino; Dilia Giuggioli; Giovanna Cuomo; Mara Rosada; Stefano Bombardieri; Silvano Todesco; Giuseppe Tirri
Journal:  Medicine (Baltimore)       Date:  2002-03       Impact factor: 1.889

2.  Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis.

Authors:  F M Wigley; R A Wise; R Miller; B W Needleman; R J Spence
Journal:  Arthritis Rheum       Date:  1992-06

3.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Authors:  J H Korn; M Mayes; M Matucci Cerinic; M Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; J R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; A Herrick; P A Merkel; R Simms; C P Denton; D Furst; N Nguyen; M Gaitonde; Carol Black
Journal:  Arthritis Rheum       Date:  2004-12

4.  Macrovascular disease and systemic sclerosis.

Authors:  M Ho; D Veale; C Eastmond; G Nuki; J Belch
Journal:  Ann Rheum Dis       Date:  2000-01       Impact factor: 19.103

5.  Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules.

Authors:  S Della Bella; M Molteni; C Mocellin; S Fumagalli; P Bonara; R Scorza
Journal:  Prostaglandins Other Lipid Mediat       Date:  2001-06       Impact factor: 3.072

6.  Peripheral vasculopathy in patients with systemic sclerosis: difference in limited and diffuse subset of disease.

Authors:  Predrag Ostojić; Nemanja Damjanov; Slavica Pavlov-Dolijanovic; Goran Radunović
Journal:  Clin Hemorheol Microcirc       Date:  2004       Impact factor: 2.375

7.  Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results.

Authors:  Paola Caramaschi; Alessandro Volpe; Ilaria Tinazzi; Lisa Maria Bambara; Antonio Carletto; Domenico Biasi
Journal:  Rheumatol Int       Date:  2006-09-28       Impact factor: 2.631

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

9.  Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Authors:  F M Wigley; R A Wise; J R Seibold; D A McCloskey; G Kujala; T A Medsger; V D Steen; J Varga; S Jimenez; M Mayes; P J Clements; S R Weiner; J Porter; M Ellman; C Wise; L D Kaufman; J Williams; W Dole
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

10.  Mortality and prognostic factors in Spanish patients with systemic sclerosis.

Authors:  C P Simeón; L Armadans; V Fonollosa; R Solans; A Selva; M Villar; J Lima; J Vaqué; M Vilardell
Journal:  Rheumatology (Oxford)       Date:  2003-01       Impact factor: 7.580

View more
  13 in total

1.  [Critical limb ischemia in systemic sclerosis].

Authors:  M O Becker; G Riemekasten
Journal:  Z Rheumatol       Date:  2012-06       Impact factor: 1.372

Review 2.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

3.  Bosentan fosters microvascular de-remodelling in systemic sclerosis.

Authors:  S Guiducci; S Bellando Randone; C Bruni; G Carnesecchi; A Maresta; F Iannone; G Lapadula; M Matucci Cerinic
Journal:  Clin Rheumatol       Date:  2012-09-29       Impact factor: 2.980

4.  Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost.

Authors:  Paola Caramaschi; Alessandra Dalla Gassa; Daniele Prati; Giovanni Barausse; Ilaria Tinazzi; Viviana Ravagnani; Silvia Confente; Domenico Biasi
Journal:  Rheumatol Int       Date:  2011-03-30       Impact factor: 2.631

Review 5.  Assessing microvascular changes in systemic sclerosis diagnosis and management.

Authors:  Maurizio Cutolo; Alberto Sulli; Vanessa Smith
Journal:  Nat Rev Rheumatol       Date:  2010-08-10       Impact factor: 20.543

Review 6.  Raynaud phenomenon and digital ulcers in systemic sclerosis.

Authors:  Michael Hughes; Yannick Allanore; Lorinda Chung; John D Pauling; Christopher P Denton; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2020-02-25       Impact factor: 20.543

7.  Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management.

Authors:  Zsuzsanna H McMahan; Fredrick M Wigley
Journal:  Int J Clin Rheumtol       Date:  2010

8.  The safety of iloprost in systemic sclerosis in a real-life experience.

Authors:  S Bellando-Randone; C Bruni; G Lepri; G Fiori; F Bartoli; M L Conforti; A Moggi-Pignone; S Guiducci; D Giuggioli; M Colaci; A Spinella; C Ferri; M Matucci-Cerinic
Journal:  Clin Rheumatol       Date:  2018-02-22       Impact factor: 2.980

9.  Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.

Authors:  Rosario Foti; Elisa Visalli; Giorgio Amato; Alessia Benenati; Giovanni Converso; Alberto Farina; Salvatore Bellofiore; Massimiliano Mulè; Marcella Di Gangi
Journal:  Rheumatol Int       Date:  2016-10-28       Impact factor: 2.631

10.  User preference for a portable syringe pump for iloprost infusion.

Authors:  Antonella Laria; Alfredo Maria Lurati; Katia Angela Re; Maria Grazia Marrazza; Daniela Mazzocchi; Alberto Farina; Magda Scarpellini
Journal:  Patient Relat Outcome Meas       Date:  2015-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.